江苏先声药业有限公司 SIMCERE PHARMACEUTICAL GROUP
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day 2022-04-19 10:28
SIMCERE PHARMA (HK.2096) to host 2022 R&D Day 2022-04-07 21:39
Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer 2022-02-24 13:34
Simcere Pharma (2096.HK) Announces a Positive Profit Alert 2022-02-23 16:22
Bijoyesh Mookerjee, M.D. named Chief Medical Officer, Oncology for Simcere Pharmaceuticals 2022-02-08 10:01
Simcere and Shanghai Institute of Materia Medica Enter a Collaboration to Jointly Develop Next-Gen COVID-19 Oral Antiviral Treatments 2021-11-23 11:22
Simcere and JW Pharmaceutical Announce Collaboration and License Agreement for Anti-Gout Drug Candidate URC-102 in China 2019-09-27 18:52
1 2